HRP20190186T4 - Nove formulacije (trimetoksifenilamino)pirimidinila - Google Patents

Nove formulacije (trimetoksifenilamino)pirimidinila Download PDF

Info

Publication number
HRP20190186T4
HRP20190186T4 HRP20190186TT HRP20190186T HRP20190186T4 HR P20190186 T4 HRP20190186 T4 HR P20190186T4 HR P20190186T T HRP20190186T T HR P20190186TT HR P20190186 T HRP20190186 T HR P20190186T HR P20190186 T4 HRP20190186 T4 HR P20190186T4
Authority
HR
Croatia
Prior art keywords
formula
compound
formulation
pharmaceutical composition
composition according
Prior art date
Application number
HRP20190186TT
Other languages
English (en)
Croatian (hr)
Inventor
Farhan Abdul Karim Alhusban
Ian Paul Gabbott
Bindhumadhavan GURURAJAN
Dawn SIEVWRIGHT
David Bradley Brook Simpson
Original Assignee
Rigel Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46875902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20190186(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.
Publication of HRP20190186T1 publication Critical patent/HRP20190186T1/hr
Publication of HRP20190186T4 publication Critical patent/HRP20190186T4/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20190186TT 2011-07-28 2012-07-26 Nove formulacije (trimetoksifenilamino)pirimidinila HRP20190186T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512621P 2011-07-28 2011-07-28
EP12759802.7A EP2736487B2 (en) 2011-07-28 2012-07-26 New (trimethoxyphenylamino)pyrimidinyl formulations
PCT/GB2012/051791 WO2013014454A1 (en) 2011-07-28 2012-07-26 New (trimethoxyphenylamino)pyrimidinyl formulations

Publications (2)

Publication Number Publication Date
HRP20190186T1 HRP20190186T1 (hr) 2019-03-22
HRP20190186T4 true HRP20190186T4 (hr) 2024-12-20

Family

ID=46875902

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190186TT HRP20190186T4 (hr) 2011-07-28 2012-07-26 Nove formulacije (trimetoksifenilamino)pirimidinila

Country Status (27)

Country Link
US (2) US8771648B2 (sr)
EP (1) EP2736487B2 (sr)
JP (1) JP6019116B2 (sr)
KR (2) KR102024120B1 (sr)
CN (1) CN103826610B (sr)
AR (1) AR087371A1 (sr)
AU (1) AU2012288632B2 (sr)
BR (1) BR112014001999B1 (sr)
CA (1) CA2843138C (sr)
CY (1) CY1122596T1 (sr)
DK (1) DK2736487T4 (sr)
EA (1) EA028432B1 (sr)
ES (1) ES2710423T5 (sr)
FI (1) FI2736487T4 (sr)
HR (1) HRP20190186T4 (sr)
HU (1) HUE042611T2 (sr)
LT (1) LT2736487T (sr)
MX (1) MX339685B (sr)
PL (1) PL2736487T5 (sr)
PT (1) PT2736487T (sr)
RS (1) RS58433B2 (sr)
SI (1) SI2736487T2 (sr)
SM (1) SMT201900071T1 (sr)
TR (1) TR201901792T4 (sr)
TW (1) TW201311251A (sr)
UY (1) UY34223A (sr)
WO (1) WO2013014454A1 (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008064274A1 (en) * 2006-11-21 2008-05-29 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses
MX339685B (es) 2011-07-28 2016-06-06 Rigel Pharmaceuticals Inc Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas.
JP6853786B2 (ja) 2015-04-02 2021-03-31 ストラ エンソ オーワイジェイ 活性化リグニン組成物、その製造方法及びその使用
WO2016172053A1 (en) 2015-04-24 2016-10-27 Rigel Pharmaceuticals, Inc. Methods of treating ibrutinib-resistant disease
SE542795C2 (en) 2018-10-08 2020-07-07 Stora Enso Oyj Process for preparing a resin
ES2988714T3 (es) * 2020-07-07 2024-11-21 Celgene Corp Composiciones farmacéuticas que comprenden (S)-4-(4-(4-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencilo)piperazin-1-il)-3-fluorobenzonitrilo y métodos de uso de las mismas
BR112023001041A2 (pt) * 2020-07-24 2023-03-07 Dsm Ip Assets Bv Comprimidos de dissolução rápida

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE369842T1 (de) 2002-03-04 2007-09-15 Orbus Pharma Inc Zusammensetzungen mit schneller freisetzung enthaltend cefuroxime axetil
DK1534286T3 (da) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
WO2005013996A2 (en) 2003-08-07 2005-02-17 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
WO2006012502A2 (en) * 2004-07-23 2006-02-02 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
AU2005289426A1 (en) * 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2006057501A1 (en) 2004-11-23 2006-06-01 Dong Wha Pharmaceutical. Ind. Co., Ltd. N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt
JP4801096B2 (ja) * 2005-01-19 2011-10-26 ライジェル ファーマシューティカルズ, インコーポレイテッド 2,4−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US8246984B2 (en) * 2005-12-06 2012-08-21 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
JP4653842B2 (ja) * 2006-02-17 2011-03-16 ライジェル ファーマシューティカルズ, インコーポレイテッド 自己免疫疾患を治療または予防するための2,4−ピリミジンジアミン化合物
US20090048214A1 (en) * 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
WO2008064274A1 (en) * 2006-11-21 2008-05-29 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses
US20090012045A1 (en) * 2007-06-26 2009-01-08 Rigel Pharmaceuticals, Inc. Methods of Treating Cell Proliferative Disorders
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
UA102825C2 (ru) * 2007-11-07 2013-08-27 Райджел Фармасьютикалз, Инк. Фармацевтическая композиция, полученная влажным гранулированием с использованием вещества, которое связывает воду
SI2252300T1 (sl) 2008-02-22 2017-04-26 Rigel Pharmaceuticals, Inc. Uporaba 2,4-pirimidindiaminov za zdravljenje ateroskleroze
UA108077C2 (xx) 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
WO2011009075A2 (en) 2009-07-17 2011-01-20 Rigel Pharmaceuticals, Inc. Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
US8389515B2 (en) 2009-11-20 2013-03-05 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs and their uses
ES2562419T3 (es) 2010-04-13 2016-03-04 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidinodiamina y sus profármacos y sus usos
MX339685B (es) 2011-07-28 2016-06-06 Rigel Pharmaceuticals Inc Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas.

Also Published As

Publication number Publication date
SI2736487T2 (sl) 2025-06-30
RS58433B2 (sr) 2025-01-31
SMT201900071T1 (it) 2019-02-28
TR201901792T4 (tr) 2019-03-21
UY34223A (es) 2013-02-28
EP2736487B2 (en) 2024-08-28
US20130058876A1 (en) 2013-03-07
HUE042611T2 (hu) 2019-07-29
AR087371A1 (es) 2014-03-19
MX339685B (es) 2016-06-06
MX2014001065A (es) 2014-08-01
HRP20190186T1 (hr) 2019-03-22
AU2012288632B2 (en) 2017-08-17
LT2736487T (lt) 2019-02-25
EA201490363A1 (ru) 2014-06-30
BR112014001999A2 (pt) 2017-02-21
ES2710423T3 (es) 2019-04-25
CY1122596T1 (el) 2021-01-27
AU2012288632A1 (en) 2014-02-20
ES2710423T5 (en) 2025-02-13
JP6019116B2 (ja) 2016-11-02
JP2014521630A (ja) 2014-08-28
CN103826610A (zh) 2014-05-28
KR102024120B1 (ko) 2019-09-23
BR112014001999B1 (pt) 2023-11-28
EP2736487A1 (en) 2014-06-04
CN103826610B (zh) 2017-08-04
US8951504B2 (en) 2015-02-10
KR20140058576A (ko) 2014-05-14
WO2013014454A1 (en) 2013-01-31
RS58433B1 (sr) 2019-04-30
PL2736487T3 (pl) 2019-06-28
TW201311251A (zh) 2013-03-16
CA2843138A1 (en) 2013-01-31
CA2843138C (en) 2020-06-02
US20140271493A1 (en) 2014-09-18
US8771648B2 (en) 2014-07-08
SI2736487T1 (sl) 2019-04-30
FI2736487T4 (fi) 2024-10-31
PT2736487T (pt) 2019-02-13
HK1198741A1 (en) 2015-06-05
EP2736487B1 (en) 2018-11-07
KR20190109576A (ko) 2019-09-25
EA028432B1 (ru) 2017-11-30
PL2736487T5 (pl) 2025-01-27
DK2736487T4 (da) 2024-11-04
DK2736487T3 (en) 2019-03-04
KR102090440B1 (ko) 2020-03-17

Similar Documents

Publication Publication Date Title
HRP20190186T4 (hr) Nove formulacije (trimetoksifenilamino)pirimidinila
HRP20200046T1 (hr) Formulacije apiksabana
HRP20170241T2 (hr) Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
FI3470063T3 (fi) Lääkekoostumuksia cftr-välitteisten sairauksien hoitoon
RU2011141496A (ru) Таблетки и гранулированные порошки, содержащие 6-фтор-3-гидрокси-2-пиразинкарбоксамид
HRP20210516T2 (hr) Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
SG10201804024VA (en) Formulations of azaindole compounds
HRP20151009T1 (hr) Dvoslojna tableta koja sadrži elvitegravir, kobicistat, emtricitabin i tenofovir
HRP20161262T1 (hr) Tablete ulipristal acetata
HRP20211423T1 (hr) Formulacije enzalutamida
WO2011146583A3 (en) Nanoparticulate cinacalcet formulations
NZ611467A (en) Rapidly dispersing granules, orally disintegrating tablets and methods
HRP20180425T1 (hr) Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
HRP20161329T1 (hr) Oralni oblici doziranja koji sadrže likarbazepin acetat
CA2601955A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
TN2012000246A1 (en) Pharmaceutical compositions comprising sigma receptor ligands
HRP20251373T1 (hr) Mikroporozni cirkonijev silikat za liječenje hiperkalijemije
JP2011525501A5 (sr)
HRP20240720T1 (hr) Farmaceutski pripravak, koji sadrži čestice fosfatnog veziva
HRP20151347T1 (hr) Nova kombinacija
HRP20240605T1 (hr) Kristalni oblici eravaciklina
HRP20191217T1 (hr) Čvrsti farmaceutski sastav citizina i postupak pripreme istog
JP2012001473A5 (sr)
JP2012105574A5 (sr)
CN104622827A (zh) 托法替布片剂及其制备方法